Q3 EPS Estimate for Artiva Biotherapeutics Cut by Analyst

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.90) per share for the quarter, down from their prior estimate of ($0.74). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.55) EPS, FY2026 earnings at ($4.16) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($1.04) EPS.

Separately, Needham & Company LLC dropped their price objective on Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $17.80.

Artiva Biotherapeutics Price Performance

ARTV opened at $2.56 on Monday. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $17.31. The stock’s fifty day moving average is $2.20 and its 200-day moving average is $2.94.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.03).

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN grew its holdings in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Artiva Biotherapeutics by 3.8% in the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after acquiring an additional 4,335 shares during the last quarter. Barclays PLC grew its holdings in shares of Artiva Biotherapeutics by 23.2% in the 4th quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after acquiring an additional 4,545 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Artiva Biotherapeutics by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after acquiring an additional 6,828 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Artiva Biotherapeutics by 262.1% in the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock worth $100,000 after acquiring an additional 7,151 shares during the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.